Researcher at Anasys Instruments, United States, and University of Illinois Urbana-Champaign, United States, present in ACS Nano a nanofabrication, chemical identification, and nanometer-scale chemical imaging of polymer nanostructures with better than 100nm spatial resolution. The new diagnostic tools that can support cutting-edge nanomanufacturing.
Jonathan R. Felts, Kevin Kjoller, Michael Lo, Craig B. Prater, and William P. King: Nanometer-Scale Infrared Spectroscopy of Heterogeneous Polymer Nanostructures Fabricated by Tip-Based Nanofabrication, In: ACS Nano, Volume 6, Issue 9, September 25, 2012, Pages 8015-8021, DOI:10.1021/nn302620f:
http://dx.doi.org/10.1021/nn302620f
http://www.anasysinstruments.com/
B.E.S.S. Technologies (B.E.S.S.), and CNSE of the University at Albany (US) has entered into a licensing agreement with its first student spin-off company, which will allow B.E.S.S. to commercialize and begin scale-up of its innovative battery storage technology, enabling homegrown high-tech growth in upstate New York. B.E.S.S., which stands for Battery Energy Storage Systems, is a component design and engineering firm started by a group of CNSE graduate students in 2010. Working at CNSE’s Albany NanoTech Complex, B.E.S.S. developed an innovative process to build nanostructures which offer significantly increased energy storage capacity, faster charging rates, and a longer lifetime for lithium-ion batteries. CNSE has already assisted B.E.S.S. in obtaining more than $800,000 in funding through technology programs offered by the New York State Energy Research and Development Authority (NY- SERDA) and the National Science Foundation’s (NSF) Partnerships for Innovation program.
http://www.cnse.albany.edu
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins™, announced that the United States Patent and Trademark Office has recently issued five US patents to the company. The patents cover BIND- 014, the company’s lead Accurin product candidate for solid cancer tumors, and its Medicinal Nanoengineering™ platform which enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites. The newly-issued patents include:
• US Patent 8,246,968 and US Patent 8,236,330: Both of these patents relate to BIND-014 and its targeting ligand.
• US 8,206,747 relates to the polymer composition of BIND-014 and US Patent 8,211,473 relates to a lyophilized composition of BIND-014. Both of these patents cover BIND-014 and BIND’s Medicinal Nanoengineering platform.
• US Patent 8,193,334 relates to BIND’s Medicinal Nanoengineering platform.
http://www.bindbio.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93